Wells Fargo & Company Passage Bio, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.86 - $1.73 $4 - $8	5 Added 1.64%	309 $0
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.01 $9 - $16	16 Added 5.56%	304 $0
Q3 2023 Nov 13, 2023	BUY	$0.66 - $1.01 $29 - $44	44 Added 18.03%	288 $0
Q2 2023 Aug 15, 2023	SELL	$0.82 - $1.19 $237 - $345	-290 Reduced 54.31%	244 $0
Q1 2023 May 12, 2023	BUY	$0.96 - $1.88 $291 - $571	304 Added 132.17%	534 $0
Q4 2022 Feb 13, 2023	SELL	$1.06 - $1.48 $417 - $583	-394 Reduced 63.14%	230 $0
Q3 2022 Nov 14, 2022	SELL	$1.22 - $2.48 $14 - $29	-12 Reduced 1.89%	624 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.63 - $3.46 $4,200 - $8,916	-2,577 Reduced 80.21%	636 $2,000
Q1 2022 May 16, 2022	SELL	$2.66 - $6.49 $35,221 - $85,934	-13,241 Reduced 80.47%	3,213 $10,000
Q4 2021 Feb 14, 2022	BUY	$6.24 - $10.2 $98,847 - $161,578	15,841 Added 2584.18%	16,454 $105,000
Q3 2021 Nov 15, 2021	BUY	$9.73 - $15.52 $1,216 - $1,940	125 Added 25.61%	613 $6,000
Q2 2021 Aug 16, 2021	SELL	$12.44 - $19.45 $7,090 - $11,086	-570 Reduced 53.88%	488 $6,000
Q1 2021 May 13, 2021	SELL	$16.24 - $29.83 $140,735 - $258,506	-8,666 Reduced 89.12%	1,058 $19,000
Q4 2020 Feb 09, 2021	BUY	$14.28 - $29.73 $82,152 - $171,036	5,753 Added 144.88%	9,724 $248,000
Q3 2020 Nov 05, 2020	SELL	$12.39 - $26.15 $36,649 - $77,351	-2,958 Reduced 42.69%	3,971 $52,000
Q2 2020 Aug 13, 2020	BUY	$14.59 - $36.07 $101,094 - $249,929	6,929 New	6,929 $189,000

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $35.9M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.